{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:15:40Z","timestamp":1772039740252,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900166, 82270179, 82300164"],"award-info":[{"award-number":["81900166, 82270179, 82300164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900166, 82270179, 82300164"],"award-info":[{"award-number":["81900166, 82270179, 82300164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900166, 82270179, 82300164"],"award-info":[{"award-number":["81900166, 82270179, 82300164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221287, BK20230296"],"award-info":[{"award-number":["BK20221287, BK20230296"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221287, BK20230296"],"award-info":[{"award-number":["BK20221287, BK20230296"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Project of Jiangsu Commission of Health","award":["M2022123"],"award-info":[{"award-number":["M2022123"]}]},{"name":"Social Development Foundation of Zhenjiang","award":["SH2022027, SH2023009"],"award-info":[{"award-number":["SH2022027, SH2023009"]}]},{"name":"Social Development Foundation of Zhenjiang","award":["SH2022027, SH2023009"],"award-info":[{"award-number":["SH2022027, SH2023009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Philadelphia chromosome positive (Ph<jats:sup>+<\/jats:sup>) acute lymphoblastic leukemia (ALL) refers to ALL patients with t(9;22) cytogenetic abnormalities, accounting for about 25% of ALL. Lung adenocarcinoma (LUAD) is the most common pathological type of non-small-cell lung cancer, which has a frequency of approximately 45% cases with mutations in EGFR. Both Ph<jats:sup>+<\/jats:sup> ALL and EGFR mutant LUAD are involved in the pathogenesis of the abnormal activation of the tyrosine kinase pathway. Although the second primary hematological malignancy after the treatment of solid tumors is common in clinics, the synchronous multiple primary malignant tumors of hematological malignancy overlap solid tumors are uncommon, even both tumors involved in the pathogenesis of the abnormal activation of the tyrosine kinase pathway are extremely rare.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An 84-year-old man with fatigue and dizziness was diagnosed with Ph<jats:sup>+<\/jats:sup> ALL. Meanwhile, a chest CT indicated a space-occupying lesions, characterized by the presence of void, in the right lower lope with the enlargement of mediastinal lymph node and right pleural effusion. After a few weeks, the patient was diagnosed with LUAD with EGFR exon 19 mutation. Both tyrosine kinase inhibitors (TKI) (Flumatinib) and EGFR-TKI (Oxertinib) was used for the patients, and finally have controlled both diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>As far as we know, we for the first time reported a case of Ph<jats:sup>+<\/jats:sup> ALL and EGFR mutant LUAD synchronous overlap, of which pathogenesis is related to abnormal tyrosine kinase activation. This patient was successfully treated with two different TKIs without serious adverse events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-024-01955-y","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T16:03:17Z","timestamp":1720454597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of Ph+ acute lymphoblastic leukemia and EGFR mutant lung adenocarcinoma synchronous overlap: may one TKI drug solve two diseases?"],"prefix":"10.1186","volume":"17","author":[{"given":"Qi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-qiang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"11","key":"1955_CR1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/jamaoncol.2017.0465","volume":"3","author":"THM Keegan","year":"2017","unstructured":"Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult Cancer survivors. JAMA Oncol. 2017;3(11):1554\u20137.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1955_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.beha.2019.02.012","volume":"32","author":"GS Guru Murthy","year":"2019","unstructured":"Guru Murthy GS, Abedin S. Myeloid malignancies after treatment for solid tumours. Best Pract Res Clin Haematol. 2019;32(1):40\u20136.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"1955_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12920-021-01147-y","volume":"14","author":"Y Feng","year":"2021","unstructured":"Feng Y, Chen X, Jiang K, Zhang D, Tao F, Ni D, Zhang J, Wu L, Cai J, Jiang L, Yu G, Shi L. Secondary myelodysplastic syndromes identified via next-generation sequencing in a non-small cell lung cancer patient. BMC Med Genomics. 2021;14(1):299.","journal-title":"BMC Med Genomics"},{"issue":"2","key":"1955_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1245\/s10434-015-4885-5","volume":"23","author":"F Shoji","year":"2016","unstructured":"Shoji F, Yamazaki K, Kouso H, Mori R, Takase K, Okamura S, Takeo S. Clinicopathological features and outcome of Lung Cancer patients with hematological malignancy. Ann Surg Oncol. 2016;23(2):633\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"10230","key":"1955_CR5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"issue":"25","key":"1955_CR6","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMra2113347","volume":"386","author":"R Fo\u00e0","year":"2022","unstructured":"Fo\u00e0 R, Chiaretti S. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia. N Engl J Med. 2022;386(25):2399\u2013411.","journal-title":"N Engl J Med"},{"issue":"9","key":"1955_CR7","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","volume":"8","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of adults with Philadelphia chromosome-positive Acute Lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol. 2022;8(9):1340\u20138.","journal-title":"JAMA Oncol"},{"issue":"10299","key":"1955_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"1","key":"1955_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","volume":"12","author":"S Sigismund","year":"2018","unstructured":"Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3\u201320.","journal-title":"Mol Oncol"},{"issue":"3","key":"1955_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1955_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrclinonc.2009.62","volume":"6","author":"H Linardou","year":"2009","unstructured":"Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009;6(6):352\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1955_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"1955_CR13","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.3390\/cancers15205009","volume":"15","author":"I Marrocco","year":"2023","unstructured":"Marrocco I, Yarden Y. Resistance of Lung Cancer to EGFR-Specific kinase inhibitors: activation of bypass pathways and endogenous mutators. Cancers. 2023;15(20):5009.","journal-title":"Cancers"},{"issue":"8","key":"1955_CR14","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00277-020-04357-z","volume":"100","author":"AA Mian","year":"2021","unstructured":"Mian AA, Haberbosch I, Khamaisie H, Agbarya A, Pietsch L, Eshel E, Najib D, Chiriches C, Ottmann OG, Hantschel O, Biondi RM, Ruthardt M, Mahajna J. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K. Ann Hematol. 2021;100(8):2023\u20139.","journal-title":"Ann Hematol"},{"issue":"8","key":"1955_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41416-019-0428-3","volume":"120","author":"BC Creelan","year":"2019","unstructured":"Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB. Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance. Br J Cancer. 2019;120(8):791\u20136.","journal-title":"Br J Cancer"},{"key":"1955_CR16","doi-asserted-by":"publisher","first-page":"728155","DOI":"10.3389\/fonc.2021.728155","volume":"11","author":"C Kim","year":"2021","unstructured":"Kim C, Liu SV, Crawford J, Torres T, Chen V, Thompson J, Tan M, Esposito G, Subramaniam DS, Giaccone G. A phase I trial of Dasatinib and Osimertinib in TKI Na\u00efve patients with Advanced EGFR-Mutant Non-small-cell Lung Cancer. Front Oncol. 2021;11:728155.","journal-title":"Front Oncol"},{"issue":"1","key":"1955_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39.","journal-title":"J Hematol Oncol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-024-01955-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-024-01955-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-024-01955-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T16:04:05Z","timestamp":1720454645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-024-01955-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1955"],"URL":"https:\/\/doi.org\/10.1186\/s12920-024-01955-y","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed written consent was obtained from this patient for publication of this case. Consent is available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study approved by the Ethics Committee of the Affiliated People\u2019s Hospital of Jiangsu University, in compliance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"182"}}